LPTX | Leap Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.40 - 3.83
52 Week Range	1.3200 - 5.00
Beta	1.31
Implied Volatility	127.44%
IV Rank	4.32%
Day's Volume	379,339
Average Volume	222,075
Shares Outstanding	38,264,500
Market Cap	140,430,715
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-01-25

Valuation
Profitability
Growth
Health
P/E Ratio	-3.74
Forward P/E Ratio	N/A
EPS	-0.98
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	54
Country	USA
Website	LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX's peers: ABEO, ADAP, AFMD, AGEN, APTO, BLRX, CRIS, EXAI, GLMD, XFOR, TERN, DAWN, PDSB, INZY, EFTR, ELEV, MREO, HEPA, HOOK, ABOS, MBIO, MTNB, NERV, ORMP, PGEN, PIRS, RIGL, TLSA, VIRX, VYGR

*Chart delayed

Analyzing fundamentals for LPTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see LPTX Fundamentals page.

Watching at LPTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LPTX Technicals page.